Advanced Solid Malignancies Clinical Trial
Official title:
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies
Verified date | January 2024 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to investigate the safety and tolerability of continuous and/or intermittent dosing of AZD2014 when given orally to patients with advanced solid malignancies.
Status | Active, not recruiting |
Enrollment | 27 |
Est. completion date | February 28, 2025 |
Est. primary completion date | February 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: - Histological or cytological confirmation of a solid, malignant tumour that is refractory to standard therapies or for which no standard therapies exist - For Cohort 3-1 and 3-2, followed as, Histological or cytological confirmation of a solid, malignant tumour that is refractory to standard therapies or for which no standard therapies exist or where treatment with paclitaxel is an appropriate treatment option. SqNSCLC patients are excluded from the Cohort 3-2. - World Health Organisation (WHO) performance status (PS) 0-1 with no deterioration over the previous 2 weeks prior to informed consent and minimum life expectancy of 12 weeks - At least one lesion that can be accurately assessed at baseline by computed tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment Exclusion Criteria - Prior chemotherapy, biological therapy, radiation therapy, antiandrogens, other anticancer therapies including immunotherapy and any investigational agents within 21 days of starting study treatment (not including palliative radiotherapy at focal sites), or corticosteroids within 14 days of starting study treatment. - Major surgery within 4 weeks prior to the study treatment (excluding placement of vascular access), or minor surgery within 2 weeks prior to the study treatment - Potent or moderate inhibitors or inducers of cytochrome (CYP) 3A4/5 if taken within the stated washout periods: - Potent or moderate inhibitors or inducers of CYP2C8 if taken within the stated washout periods: - Exposure to sensitive or narrow therapeutic range substrates of the drug metabolising enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters P-gp (MDR1), Breast cancer resistance protein (BCRP), Organic anion transporting polypeptide (OATP)1B1, OATP1B3, Organic cation transporter (OCT)1 and OCT2 within the appropriate wash-out period (at least 5 x reported terminal elimination half-life (t1/2) of each drug) before the study treatment. - Any haemopoietic growth factors (eg, granulocyte-colony stimulating factor [G-CSF]) within 2 weeks prior to receiving study drug - Previous initiation of treatment with AZD2014 in the present study or prior treatment with AZD8055 - With the exception of alopecia, any unresolved toxicities from prior chemotherapy greater than Common toxicity criteria for adverse events (CTCAE) grade 1 at the time of starting study treatment - Spinal cord or brain metastases unless asymptomatic and stable off steroids for at least 4 weeks prior to start of study treatment - Subjects with interstitial lung disease as a complication or a history |
Country | Name | City | State |
---|---|---|---|
Japan | Research Site | Chuo-ku | |
Japan | Research Site | Kashiwa |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability measured by adverse events | This will be assessed in terms of Adverse Events (AEs), laboratory data, vital signs, ECG and physical exams | 6 months in average | |
Secondary | Cmax of AZd2014 | Characterising the pharmacokinetics (PK) of AZD2014 | 21 days | |
Secondary | AUC(Area under the plasma concentration-time curve) of AZD2014 | Characterising the pharmacokinetics (PK) of AZD2014 | 21 days | |
Secondary | Tmax of AZD2014 | Characterising the pharmacokinetics (PK) of AZD2014 | 21 days | |
Secondary | To obtain a preliminary assessment of the anti-tumour activity of AZD2014 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. | Best overall response | 6 months in average | |
Secondary | To obtain a preliminary assessment of the anti-tumour activity of AZD2014 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. | Objective response rate | 6 months in average | |
Secondary | To obtain a preliminary assessment of the anti-tumour activity of AZD2014 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. | Percentage change in tumour size | 6 months in average |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02080078 -
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
|
Phase 1 | |
Completed |
NCT00981721 -
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00351325 -
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT00295243 -
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT02347228 -
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00979134 -
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
|
Phase 1 | |
Completed |
NCT00997945 -
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT05573724 -
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT03736473 -
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
|
Phase 1 | |
Completed |
NCT02260661 -
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01213160 -
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
|
Phase 1 | |
Terminated |
NCT01219543 -
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
|
Phase 1 | |
Completed |
NCT00572364 -
Open Label, Dose Escalation Phase I Study of AZD2281
|
Phase 1 | |
Completed |
NCT03363893 -
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04606381 -
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT05315167 -
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00879905 -
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00473616 -
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
|
Phase 1 | |
Recruiting |
NCT05159700 -
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01813474 -
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
|
Phase 1 |